- Home
- RYN vs ICUI Comparison
RYN vs ICUI Comparison
Compare RYN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYN | ICUI |
|---|---|---|
| Founded | 1926 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.2B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | RYN | ICUI |
|---|---|---|
| Price | $21.90 | $146.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $27.25 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 1.6M | 255.7K |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | ★ 13.27% | N/A |
| EPS Growth | ★ 373.89 | N/A |
| EPS | ★ 5.07 | N/A |
| Revenue | $1,293,371,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.52 | ★ N/A |
| Revenue Growth | ★ 60.70 | N/A |
| 52 Week Low | $21.06 | $107.00 |
| 52 Week High | $28.31 | $175.51 |
Technical Indicators
Market Signals| Indicator | RYN | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 59.51 |
| Support Level | $21.59 | $145.32 |
| Resistance Level | $22.69 | $148.95 |
| Average True Range (ATR) | 0.58 | 4.01 |
| MACD | 0.10 | -0.63 |
| Stochastic Oscillator | 38.74 | 65.40 |
Price Performance
Historical ComparisonAbout RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.